Drug

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance
AbbVieNYSE: ABBV

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie Inc. (NYSE: ABBV) announced that China's National Medical Products Administration (NMPA) has approved RINVOQ (upadacitinib extended‑release tablets, 15 mg and 30 mg, once daily) for the treatment of adults…

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Qilu Pharmaceutical's QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Qilu Pharmaceutical’s QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
GSK's Nucala Wins CHMP Nod for COPD in Europe
GlaxoSmithKlineGSK

GSK’s Nucala Wins CHMP Nod for COPD in Europe

Novo Nordisk's Wegovy 7.2mg Gets EMA Positive Opinion for Obesity
Novo NordiskNYSE: NVO

Novo Nordisk’s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity

Innovent's Mazdutide Wins Macau Approval for Weight Management
HKG: 1801Hot targets

Innovent’s Mazdutide Wins Macau Approval for Weight Management

Akeso's Cadonilimab Wins FDA Nod for Global Phase 3 Gastric Cancer Study
Akeso BiopharmaClinical trial approval / initiation

Akeso’s Cadonilimab Wins FDA Nod for Global Phase 3 Gastric Cancer Study

Show More